Drug Profile
Research programme: fibroblast growth factor receptor antibodies - MorphoSys/ProChon Biotech
Alternative Names: Anti-FGFR-3 antibodies; FGFR-3 antibodies; Fibroblast growth factor receptor HuCAL antibody research programme - MorphoSys/ProChon BiotechLatest Information Update: 24 Oct 2021
Price :
$50
*
At a glance
- Originator MorphoSys; ProChon Biotech
- Class Antibodies
- Mechanism of Action Fibroblast growth factor inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer; Dwarfism; Musculoskeletal disorders
Most Recent Events
- 16 May 2011 ProChon Biotech has been acquired by Histogenics Corporation
- 27 Jun 2003 This compound is still in active development
- 30 Jan 2001 New profile